Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models

Oncolytic virus (OV) as a promising therapeutic agent can selectively infect and kill tumor cells with naturally inherited or engineered properties. Considering the limitations of OVs monotherapy, combination therapy has been widely explored. MEK inhibitor (MEKi) Trametinib is an FDA-approved kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, XuSha, Zhao, Jing, Zhang, Jian V., Wu, Yinglin, Wang, Lei, Chen, Xiaoqing, Ji, Dongmei, Zhou, Grace Guoying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473197/
https://www.ncbi.nlm.nih.gov/pubmed/34578339
http://dx.doi.org/10.3390/v13091758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473197/
https://www.ncbi.nlm.nih.gov/pubmed/34578339
http://dx.doi.org/10.3390/v13091758

Ejemplares similares